10:25 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Company News  |  Deals

Sanofi, Alnylam restructure RNAi therapeutics deal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained global development and commercialization rights to transthyretin (TTR)-mediated amyloidosis candidates patisiran (ALN-TTR02) and ALN-TTRsc02 after it and Sanofi (Euronext:SAN; NYSE:SNY) amended their 2012 deal. The pharma and its Sanofi Genzyme unit also gain full global rights to hemophilia candidate fitusiran (ALN-AT3, SAR439774).

Previously, Sanofi and Alnylam shared rights to fitusiran and ALN-TTRsc02, respectively, in the U.S., Canada and Western Europe, while Sanofi held exclusive rights elsewhere, respectively. Alnylam had exclusive rights to patisiran...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >